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0ABSTRACT
Background: Exenatide, a glucagon-like peptide-1
receptor agonist administered by self-injection, de-
creases plasma glucose, glycosylated hemoglobin
(HbA1c), and weight in patients with type 2 diabetes.
ITCA 650 is an investigational new drug that provides
continuous subcutaneous delivery of exenatide.
Objective: This randomized, open-label, multi-
center, 28-day study evaluated the tolerability, phar-
macodynamics, and pharmacokinetics of ITCA 650 in
patients with type 2 diabetes.
Methods: The study enrolled patients with type 2
diabetes who were receiving a stable regimen of diet
and exercise alone or a stable dose of metformin
monotherapy, thiazolidinedione monotherapy, or
metformin plus thiazolidinedione combination ther-
apy. Patients were randomized to receive 10, 20, 40,
or 80 g/d of ITCA 650 placed subcutaneously for
28 days. Plasma glucose, HbA1c, insulin, and weight
ere measured at regular intervals throughout the
tudy. Exenatide levels and anti-exenatide antibod-
es were also assessed.
Results: Forty-four patients were randomized to
treatment. From baseline to end point, significant (P
0.05) decreases in fasting plasma glucose levels, 2-hour
postprandial glucose levels, and glucose AUC curve
were seen in all treatment groups. HbA1c levels also
ecreased significantly (P  0.001) in all 4 treatment
roups. Weight was significantly (P 0.05) lowered in
he 40- and 80-g/d groups. Detectable levels of ex-
natide were noted within 12 to 24 hours of ITCA 650
lacement, reached steady state by 24 hours, and then
emained relatively steady during a plateau period un-
il device removal on day 29. Exenatide levels declined
o undetectable levels within 24 hours after removal of
he ITCA 650. The most common adverse events were
634ausea, decreased appetite, and vomiting; these were
ransient andmostlymild ormoderate in severity.Mild
ocal adverse events related to the healing process were
ommon at the placement site but abated after 1 week.
welve patients developed anti-exenatide antibodies;
owever, the pharmacokinetics of ITCA 650 were not
ltered compared with those who did not develop
ntibodies.
Conclusions: ITCA 650 provided continuous and
ontrolled subcutaneous delivery of exenatide for 28days
hatwas generallywell tolerated andproduced significant
eductions in plasma glucose, HbA1c, and weight. Fur-
ther studies are warranted to characterize the long-term
tolerability and efficacy of ITCA 650 for the treatment
of patients with type 2 diabetes. ClinicalTrials.gov
identifier: NCT01798264. (Clin Ther. 2013;35:
634–645)
2013. The Authors. Published by Elsevier
Inc.
Key words: exenatide, ITCA 650, pharmacody-
namics, pharmacokinetics, type 2 diabetes.
INTRODUCTION
In the United States, type 2 diabetes affects25.8 mil-
lion people.1 Treatment often requires daily blood glu-
The results of this study were previously presented at the Ninth Annual
Diabetes Technology Meeting; November 5–7, 2009; San Francisco,
California.
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R.R. Henry et al.cose monitoring and multiple therapeutic interven-
tions, including diet, oral hypoglycemic medications,
and/or insulin or 1 of its analogues and/or injectable
incretin mimetic agents.2 However, depending on the
tage of the disease and the treatment used, glycosy-
ated hemoglobin (HbA1c) target levels 7.0% are
chieved in approximately one half of patients admin-
stered antihyperglycemic drugs.3–6
Glucagon-like peptide-1 (GLP-1) receptor agonists
are a new class of therapeutic agents for the treatment
of type 2 diabetes that have multiple actions, including
enhancement of insulin secretion, suppression of in-
appropriately elevated glucagon secretion, slowing
of gastric emptying, and reduction of food intake
and weight.7,8 Exenatide was the first approved
GLP-1 receptor agonist and exhibits a t½ of 2.4
hours, measurable plasma levels for 10 hours, and
clinical effects that persist for8 hours after a single
subcutaneous (SC) injection.9,10
A once-weekly exenatide injection has recently been
approved for use in type 2 diabetes. This formulation
consists of microspheres containing exenatide and a
poly (lactide–co-glycolide) polymeric matrix, which
slowly releases exenatide through diffusion and ero-
sion.11 A once-weekly injection of exenatide has been
shown to significantly reduce HbA1c, fasting blood
lucose, postprandial hyperglycemia, and weight.12
Long-term studies extending to 48 weeks indicate that
continued use of exenatide BID or an exenatide once-
weekly injection for up to 4 years produces sustained
reductions in HbA1c and weight.
13,14
The main limitations of exenatide BID are the need
for BID injection and a high incidence of gastrointesti-
nal adverse effects, especially nausea and vomiting, at-
tributed to fluctuations in exenatide blood concentra-
tions with high peak blood concentrations shortly after
each administration. An additional limitation of depot
formulations of GLP-1 receptor agonists is that once
injected, the depot cannot be removed should the pa-
tient experience complications. Less nausea and vom-
iting is seen with the depot formulation of exenatide;
however, 6 to 7 weeks are required to reach steady-
state concentrations, and circulating therapeutic drug
concentrations persist10 weeks after the drug is dis-
continued. The need for SC injection with all currently
available GLP-1 receptor agonists, injection site reac-
tions/discomfort, and the inconvenience of having to
reconstitute and refrigerate the once-weekly formula-
May 2013tion may create a barrier to initial use as well as long-
term patient adherence and compliance with therapy.
ITCA 650 is a miniature osmotic pump system that
delivers zero-order, continuous SC release of exenatide
at a precise predetermined rate for up to 12 months
with a single placement.15,16 The sterile product with
imensions similar to a small matchstick is inserted
ubcutaneously in the abdominal region with a place-
ent tool by using an aseptic technique during a short
ffice procedure; the procedure can be performed by a
hysician, physician’s assistant, or other licensed prac-
itioner.15 Removal requires skin preparation and a
mall (5 mm) incision. The procedures to place, re-
ove, and replace nonbiodegradable drug delivery sys-
ems is reimbursed in the United States by insurance
ompanies and other payers.
Delivery of exenatide with this system is predicted
o result in rapid attainment and maintenance of ther-
peutic drug concentrations, provide 100%adherence/
ompliance with therapy, improve glycemic control,
nd produce a lower incidence of gastrointestinal ef-
ects due to more constant and predictable exenatide
evels.15 This Phase Ib, randomized, open-label, multi-
center, 4-week study evaluated the tolerability, phar-
macodynamics (PD), and pharmacokinetics (PK) of
ITCA 650 in patients with type 2 diabetes.
PATIENTS AND METHODS
This randomized, open-label study consisted of a
3-week screening period, a 4-week treatment period,
and a 1-week posttreatment safety follow-up period.
The primary objective of the study was to evaluate the
tolerability of ITCA 650 in patients with type 2 diabe-
tes. The secondary objectives were to characterize the
PK profile of ITCA 650 and its effects on the PD mea-
sures of glucose metabolism in patients with type 2
diabetes. The study was conducted in accordance with
the Declaration of Helsinki and the International Con-
ference onHarmonisation guidelines for GoodClinical
Practice and applicable regulatory requirements. An
institutional review board reviewed and approved the
protocol, consent form, and patient information be-
fore any patient was enrolled in the study. Written in-
formed consent was obtained from each patient at the
screening visit before performing any study procedures.
Patient Selection
Men and women between the ages of 30 and 70years with a diagnosis of type 2 diabetes for 6
635
p
C
w
h
c
n
c
t
p
w
a
i
b
o
i
c
t
c
4
P
a
s
m
p
n
p
i
s
a
D
s
t
i
f
a
A
g
h
d
o
a
Clinical Therapeuticsmonths, a stable weight, and who were treated with
diet and exercise alone or in combination with a stable
dose of metformin monotherapy, thiazolidinedione
monotherapy, or metformin plus thiazolidinedione
combination therapy (3 months before screening)
were eligible to participate. Patients were required to
have an HbA1c level 6.5% and 10%, a fasting
lasma glucose (FPG) level270 mg/dL, and a fasting
-peptide level0.8 ng/mL at screening. Patients who
ere being treated with diet and exercise alone had to
ave a FPG level126 mg/dL at screening. Women of
hildbearing potential had to have a negative preg-
ancy test result at screening and agree to use an ac-
eptable form of contraception during the study.
Patients were excluded if they previously had been
reated with exenatide; had received sulfonylureas, di-
eptidyl peptidase-IV inhibitors, acarbose, or insulin
ithin 3 months of screening; or had been treated with
n investigational agent within 30 days before screen-
ng. Patients with type 1 diabetes or a history of dia-
etic ketoacidosis were excluded, as were those with
ther medical conditions that could complicate partic-
pation in the trial.
Study Procedures
Patients were admitted for a 5-day inpatient stay
and randomized on a 1:1 basis to receive either 10 or
20 g/d of ITCA 650 on study day 1. Once it was
onfirmed that the 10- and 20-g/d doses were well
olerated, an additional cohort of patients was re-
ruited and randomized to receive either 40 or 80
g/d of ITCA 650. All patients were followed up for
weeks, and the device was removed on day 29.
atients were followed up for an additional 7 days
fter the device was removed for evaluation of
afety. The randomization code and allocation were
anaged by a contract research organization (Med-
ace, Inc., Cincinnati, OhioMedpace, Inc., Cincin-
ati, Ohio).
Site personnel placed ITCA 650 study devices with a
lacement tool subcutaneously into 1 of the 4 abdom-
nal quadrants by using an aseptic technique (see De-
cription in Supplemental Table in the online version
t http://dx.doi.org/10.1016/j.clinthera.2013.03.011).
uring removal, the ITCA 650 is immobilized, and a
mall (5 mm) incision is made directly over 1 end of
he device, which is then gently pushed toward the
ncision and removed with a hemostat. u
636Study Assessments
Patients underwent a complete physical examina-
tion, including vital signs (heart rate, blood pressure,
and temperature) at screening and on day 29 (or
sooner, if early termination occurred), followed by a
brief physical examination on days 1, 8, 15, 22, and
36. A 12-lead ECGwas obtained at screening and days
1, 5, and 29 or at the time of early termination. A
3-hour breakfast meal tolerance test was obtained on
days 1, 5, 15, and 29 or upon early termination.
Safety was assessed from adverse events, clinical
laboratory test results, physical examination, vital
signs (heart rate, blood pressure, and body tempera-
ture), and ECG findings. Adverse events were reported
by patients or assessed by clinicians, and they were
categorized as either mild (transient and not interfering
with activities of daily living), moderate (causing a low
level of inconvenience possibly interfering with activi-
ties of daily living and ameliorated by simple therapeu-
tic measures), or severe (interrupting the usual daily
activities and requiring systemic drug therapy or other
treatment).
All fasting laboratory samples were collected after a
10-hour fast, and a central laboratory was used for
all study-related tests. Laboratory evaluations were
performed at screening, day1, day 1, days 2 to 5, and
days 8, 15, 22, and 29 or upon early termination. Pa-
tients used a home glucose monitor to measure FPG
each morning before breakfast. Other PD variables
were assessed at regular intervals, including weight,
insulin, proinsulin, C-peptide, glucagon, HbA1c, and
ructosamine. Two-hour postprandial glucose, insulin,
nd glucagon plasma concentrations were measured.
UC values were determined for glucose, insulin, and
lucagon. -cell function was assessed by using the
omeostasis model index (HOMA)-, and insulin re-
sistance was assessed according to HOMA–insulin
resistance. Total cholesterol, triglycerides, LDL-C,
HDL-C, and nonesterified fatty acid levels also were
determined. Insulin, proinsulin, C-peptide, and gluca-
gon levels were determined by using an electrochemi-
luminescence immunoassay. Fructosamine, glucose,
lipid and lipoprotein, and free fatty acid levels were
determined by using photometry. HbA1c levels were
etermined according to HPLC.
Blood was obtained for PK analysis at baseline and
n day 1; days 2 to 5; days 8, 15, and 22; before and
fter removal of the ITCA 650 device on day 29 or
pon early termination; and on days 30 and 36. Plasma
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R.R. Henry et al.was shipped on dry ice to Midwest Bioresearch, LLC
(Skokie, Illinois) for the determination of plasma ex-
enatide concentrations, which were measured by using
a validated electrochemiluminescent method with a
lower limit of quantitation of 29.3 pg/mL. Cmax and
Tmax were determined over the entire study period.
Cmin and Tmin were determined from 24 through 672
ours after placement. CSS was determined as the av-
rage of all concentrations measured between 24 hours
nd 672 hours after placement. AUCSS was determined
as AUCSS CSS * 24 hours. Concentrations below the
ssay limit of quantitation were assigned a value equal
o the lower limit of quantitation (29.3 pg/mL). Nom-
nal time points for each sample were used in the PK
nalysis. PK and statistical calculations were per-
ormed by using Microsoft Excel 2000 version 9.0 and
icrosoft Office Excel 2007 (Microsoft Corporation,
edmond, Washington).
Anti-exenatide antibodies were measured from
lood samples obtained on day 1 before placement of
TCA 650, on day 29 (or upon early termination), and
n day 36. Serum was obtained and shipped on dry ice
o Midwest Bioresearch. Antibody screening was con-
ucted at Midwest Bioresearch by using a validated
LISA procedure.
Statistical Analysis
One hundred fifty-one patients were screened to en-
sure that at least 40 and up to 48 patients were ran-
domized between 4 treatment groups of 10 to 12 pa-
tients each. The analysis of data from this study was
primarily exploratory in nature, and no formal hy-
pothesis was tested. The safety population consisted of
all patients randomized to treatment who received
study medication. The evaluable population consisted
of randomized patients who received complete pre-
treatment and posttreatment PD assessments. The PK
population consisted of randomized patients who re-
ceived study medication and provided at least 1 PK
sample.
An ANCOVA model with treatment as a factor
and baseline value as a covariate was used to test the
treatment effect for the change from baseline to end
point in 2-hour postprandial values and percent
change from baseline for glucose, insulin, and gluca-
gon AUC. Least-squares (LS) means, SEs, 2-tailed
95% CIs, and P values of statistical tests for each
reatment group were estimated. Values for AUC
ere transformed to a logarithmic scale before fit-
May 2013ing the model. LS means and 95% CIs were back-
ransformed to the original scale. The 95% CIs and
values for change from baseline to each scheduled
isit in 2-hour postprandial values, and percent
hange (and ratio) from baseline for AUC, was based
n a 1-sample t test. For changes from baseline to
nd point in HOMA indices, FPG, HbA1c, and fruc-
tosamine, an ANCOVA model with treatment as a
factor and baseline value as a covariate was used to
test the treatment effect. The LS means, SEs, 2-tailed
95% CIs, and P values for each treatment group
were estimated. For all scheduled visits, 95% CIs
and P values were calculated from a 1-sample t test.
Demographic characteristics, adverse events, im-
munogenicity, and laboratory parameters were sum-
marized descriptively. PK parameters were analyzed
according to treatment group by using standard non-
compartmental methods, and the results are summa-
rized descriptively.
RESULTS
The study was initiated on February 2, 2009, and
completed on May 15, 2009; a total of 44 patients
were randomized to ITCA 650 treatment and re-
ceived study drug. Five patients discontinued from
participation in the study: 1 patient in the 10-g/d
group withdrew consent for participation in the
study due to an elevated amylase level and lipase
levels, which had resolved before the device was re-
moved. One patient in the 80-g/d group discontin-
ued from the study due to orthostatic hypotension
associated with moderate nausea and vomiting.
Three patients in the 80-g/d group withdrew con-
ent for participation in the study; all had experi-
nced nausea and vomiting.
At baseline, 59.1% of patients were men; mean (SD)
ge was 55.7 (6.92) years, mean body mass index was
2.2 (4.33) kg/m2, and mean duration of diabetes was
5.9 (4.12) years (Table I). Mean HbA1c was 7.6%, and
84% of patients were receiving pharmacologic therapy
for diabetes.
Pharmacokinetics
Plasma exenatide levels were below the level of
quantitation (29.3 pg/mL) at baseline.Within 12 hours
of ITCA 650 placement, 32 of the 44 patients had
detectable levels of exenatide.Mean plasma concentra-
tions reached a plateau at 24 hours, and plasma ex-
enatide levels were maintained for the remainder of the
637
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Clinical Therapeutics28 days of treatment (Figure 1). Plasma exenatide lev-
els declined rapidly after ITCA 650 was removed, and
by 24 hours, had fallen below the level of quantitation
in all patients. Mean Cmax, Css, Cmin, and AUCss for
exenatide increased proportionally over the dose range
from 10 to 80 g/d (Table II). Median Tmax did not
ary among the 4 doses of ITCA 650.
PD Effects
Mean FPG decreased significantly (P  0.01) from
baseline to end point in the 20-, 40-, and 80-g/d
Table I. Baseline demographic and clinical character
Characteristic
IT
10 g/d (n  12) 20 g/
Mean (SD) age, y 56.3 (6.74) 57.2
Male, no. (%) 8 (66.7) 7
Race, no. (%)
White 9 (75.0) 9
Black or African American 3 (25.0) 2
Other* 0
Mean (SD) weight, kg 95.7 (16.66) 94.3
Mean (SD) BMI, kg/m2 33.1 (4.34) 32.0
Mean (SD) duration of diabetes, y 7.8 (4.72) 5.8
Treatment regimen, no. (%)
Diet  exercise 1 (8.3)
Diet  exercise  metformin 11 (91.7) 10
Diet  exercise  TZD and
metformin 0 1
BMI  body mass index; TZD  thiazolidinedione.
*Asian, American Indian or Alaskan Native, and other.
400 ITCA 6
ITCA 6350
300
250
200
150
100
50
0
0 3 6 9 12 1
Tim
M
ea
n 
Ex
en
at
id
e
P
la
sm
a 
C
on
ce
nt
ra
ti
on
 (
pg
/m
L)
Figure 1. Mean plasma exenatide concentrations ove638roups of ITCA 650 (Table III). A dose-proportional
hange from baseline was noted for FPG at each time
oint (Figure 2). Similarly, 2-hour PPG decreased sig-
ificantly (P  0.05) from baseline to end point in the
0-, 40-, and 80-g/d groups; mean changes were dose
roportional (Figure 3). Mean HbA1c levels decreased
significantly (P  0.001) from baseline to end point in
all treatment groups. Mean plasma fructosamine levels
decreased significantly (P 0.01) from baseline to end
point in all dose groups. Plasma glucose AUC de-
creased significantly (P 0.001) during meal tolerance
0 Treatment Groups
Total (N  44)11) 40 g/d (n  10) 80 g/d (n  11)
52.6 (9.54) 56.5 (4.84) 55.7 (6.92)
4 (40.0) 7 (63.6) 26 (59.1)
6 (60.0) 10 (90.9) 34 (77.3)
2 (20.0) 1 (9.1) 8 (18.2)
2 (20.0) 0 2 (4.5)
) 88.4 (18.19) 89.5 (18.25) 92.1 (17.49)
32.9 (4.62) 30.9 (3.86) 32.2 (4.33)
6.3 (5.29) 3.7 (2.51) 5.9 (4.12)
2 (20.0) 4 (36.4) 7 (15.9)
8 (80.0) 6 (54.5) 35 (79.5)
0 1 (9.1) 2 (4.6)
µg/d (n = 12)
µg/d (n = 10)
ITCA 650 20 µg/d (n = 11)
ITCA 650 80 µg/d (n = 11)
18 21
 Insertion (d)
24 27 30 33 36
e.istics.
CA 65
d (n 
(6.10)
(63.6)
(81.8)
(18.2)
0
(18.40
(4.71)
(2.77)
0
(90.9)
(9.1)50 10 
50 40 
5
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R.R. Henry et al.tests from baseline to end point for the 20-, 40-, and
80-g/d groups. The ratio of end point to pretreatment
AUC was 0.91, 0.80, 0.79, and 0.76 for the 10-, 20-,
40-, and 80-g/d doses, respectively. No significant
changes were observed for insulin AUC or glucagon
AUC, except for a significant (P  0.001) increase in
insulin AUC for the 10-g/d group.
No consistent changes were observed in mean fast-
ng plasma insulin, C-peptide levels, or 2-hour post-
randial insulin. In the 10-g/d group, significant (P
0.05) increases in 2-hour postprandial insulin were ob-
served (Table III). Significant increases were observed
from baseline to end point in mean HOMA- in the
40- and 80-g/d groups (P  0.05).
Total cholesterol (P  0.015) and LDL-C (P 
0.046) were significantly lower in the 40-g/d group.
No other significant changes from baseline to end point
were observed for lipid parameters. Mean weight de-
creased from baseline to day 29 in all treatment groups.
The mean change ranged from 0.2 kg for 10 g/d to
3.0 kg for 80 g/d (P  0.001) (Table III).
Tolerability
Overall, ITCA 650 was very well tolerated. All ad-
verse events were mild or moderate in severity, except
for 1 patient in the 80-g/d dose group who experi-
enced severe nausea and vomiting. Adverse events
tended to abate after the first week. No patient experi-
enced a serious adverse event during the trial, and no
patients died. Themost common adverse events related
to ITCA 650 were nausea (41%), decreased appetite
(36%), vomiting (27%), early satiety (11%), and diz-
ziness (9%) (Table IV). A trend toward increased ad-
verse events was observed in the higher dose groups.
Table II. Pharmacokinetic parameters for ITCA 650 d
Parameter
I
10 g/d (n  12) 20 g/
Cmax, pg/mL 65 (31) 150
Tmax, h 96
Cmin, pg/mL 30.3 (3.8) 39.2
Tmin, h 24
Css, pg/mL 38.1 (11.7) 75.8
AUCss, pg*h/mL 912 (280) 1820The proportion of patients who experienced no epi-
May 2013sodes of nausea or vomiting at weekly intervals ap-
proached 100% in all groups, with the exception of the
80-g/d group during weeks 1 and 2 (Figure 4).
The most common local adverse events related to
ITCA 650 were local incision site complication
(50%), injection site erythema (48%), incision site
hemorrhage (27%), incision site pain (23%), inci-
sion site edema (16%), and injection site blister
(11%). No dose relationship was observed for these
local adverse events. Most of the placement site reac-
tions disappeared after 1 week. No patients were ter-
minated from the study due to placement/removal site
reactions.
Two patients experienced an adverse event that led
to the removal of ITCA 650. One patient in the 10-
g/d group experienced an increase in serum amylase
and lipase, which led to removal of the ITCA 650 on
day 13. The elevation of amylase and lipase resolved in
this patient before removal of ITCA 650. A patient in
the 80-g/d group experienced moderate nausea and
vomiting and orthostatic hypotension, which resolved
after ITCA 650 was removed on day 6. In addition, 3
patients in the 80-g/d group terminated the study pre-
aturely on day 8, day 14, and day 15, respectively,
or nausea and vomiting. One patient in the 40-g/d
group who was receiving metformin was reported to
have asymptomatic hypoglycemia, and 1 patient in
the 80-g/d group who was receiving pioglitazone/
metformin combination therapy experienced a single
symptomatic episode of hypoglycemia. Both events
were considered by the investigator to be mild in inten-
sity, and neither event was considered related to the
study drug.
There were no clinically significant treatment-asso-
groups. Values are given as mean (SD) or median.
50 Treatment Groups
11) 40 g/d (n  10) 80 g/d (n  11)
253 (147) 572 (268)
105 102
2) 51.1 (32.8) 92.1 (64.8)
87 168
7) 124.0 (73.5) 290.0 (117.0)
) 2979 (1764) 6957 (2799)ose
TCA 6
d (n 
(63)
108
(18.
48
(33.
(809ciated trends in vital signs or physical examination
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Clinical TherapeuticsTable III. Change from baseline to end point (day 29) for pharmacodynamic variables (evaluable population).
Variable
ITCA 650 Treatment Groups
10 g/d (n  12) 20 g/d (n  11) 40 g/d (n  10) 80 g/d (n  11)
Mean (SD) baseline FPG, mg/dL 161.2 (33.47) 170.5 (23.05) 171.8 (35.33) 145.1 (14.61)
LS mean (SE) change 5.8 (8.86) 28.8 (9.38) 39.3 (9.86) 33.5 (9.71)
P* 0.518 0.004 0.001 0.001
Mean (SD) baseline 2-hour
postprandial glucose, mg/dL 236.4 (68.08) 245.5 (38.38) 237.0 (72.83) 249.5 (59.95)*
LS mean change 17.5 33.9 48.3 67.8
P* 0.170 0.014 0.001 0.001
Mean (SD) baseline 2-hour
postprandial insulin, mIU/mL 90.5 (71.17) 82.7 (39.60) 69.9 (32.17) 96.6 (67.15)*
LS mean change 48.9 22.4 37.3 1.1
P* 0.007 0.215 0.055 0.955
Mean (SD) baseline HbA1c, % 7.7 (1.27) 7.9 (0.76) 7.5 (0.96) 7.4 (0.96)
LS mean (SE) change 0.5 (0.09) 0.6 (0.09) 0.5 (0.10) 0.6 (0.09)
P 0.001 0.001 0.001 0.001
Mean (SD) baseline
fructosamine, mmol/L 265.9 (46.15) 278.2 (28.45) 271.9 (42.61) 260.5 (54.79)
LS mean (SE) change 17.5 (6.25) 25.5 (6.56) 33.0 (6.84) 28.7 (6.55)
P 0.008 0.001 0.001 0.001
Mean (SD) baseline weight, kg 95.7 (16.66) 94.3 (18.40) 88.4 (18.19) 89.5 (18.25)
LS mean (SE) change 0.2 (0.43) 0.2 (0.45) 1.2 (0.47) 3.0 (0.45)
P 0.675 0.617 0.013 0.001
Mean (SD) baseline insulin,
mIU/mL 14.9 (5.89) 16.9 (7.91) 13.8 (8.43) 12.4 (7.73)
LS mean (SE) change 9.6 (6.79) 2.6 (7.18) 5.7 (7.44) 6.4 (7.52)
P* 0.164 0.724 0.450 0.402
Mean (SD) baseline HOMA- 65.2 (36.14) 58.0 (30.43) 51.8 (30.24) 63.8 (41.52)
LS mean (SE) change 33.0 (19.54) 29.6 (20.34) 57.6 (21.47) 59.0 (21.36)
P* 0.100 0.153 0.011 0.009
Mean (SD) baseline HOMA-IR, % 5.7 (2.20) 7.2 (3.43) 5.6 (3.59) 4.1 (2.52)
LS mean (SE) change 5.2 (3.57) 0 (3.85) 0.8 (3.91) 2.3 (4.04)
P* 0.150 1.000 0.838 0.580
Mean (SD) baseline proinsulin,
mU/mL 29.8 (12.26) 35.0 (21.87) 34.6 (15.81) 25.5 (20.22)
LS mean (SE) change 2.4 (3.40) 0.1 (3.57) 4.8 (3.74) 12.9 (3.59)
P 0.488 0.969 0.205 0.001
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R.R. Henry et al.findings observed. There were infrequent, sporadic oc-
currences of elevated amylase and lipase, which were
not related to treatment group. There were no clini-
cally significant changes in thyroid-stimulating hor-
mone, calcitonin, hematology, serum chemistry, or uri-
nalysis values.
Antibodies
Serum anti-exenatide antibodies were absent in all
patients at baseline but were found in 12 patients on
day 29, day 30, and/or day 36 (3, 4, 4, and 1 patient
receiving 10, 20, 40, and 80 g/d of ITCA 650, respec-
Table III (continued).
Variable 10 g/d (n  12)
Mean (SD) baseline C-peptide,
ng/mL 3.5 (0.96)
LS mean (SE) change 0.7 (0.57)
P 0.232
Mean (SD) baseline glucagon,
pg/mL 100.6 (37.88)
LS mean (SE) change 4.1 (22.38)
P 0.857
FPG  fasting plasma glucose; LS  least squares; HbA1c 
IR  insulin resistance.
*Analysis of covariance with baseline as covariate and treatm
†2h postprandial glucose and 2h postprandial insulin for th
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Figure 2. Mean fasting plasma glucose levels over
time with 4 doses of ITCA 650.May 2013tively). Of note, none of the 5 patients who terminated
early (between days 6 and 15) were antibody positive
at termination or at 7 days posttermination. Antibody
titers in patients who were confirmed positive for an-
tibodies ranged from 20 to 18,330; there was no
clear relationship to treatment group. The presence of
antiexenatide antibodies did not seem to alter the PK
profile of ITCA 650.
ITCA 650 Treatment Groups
g/d (n  11) 40 g/d (n  10) 80 g/d (n  11)
3.9 (1.40) 3.7 (1.55) 2.7 (0.86)
0.6 (0.61) 0.7 (0.63) 0.9 (0.63)
0.330 0.298 0.146
8.3 (20.12) 86.1 (23.48) 81.1 (49.60)
5.7 (23.04) 11.7 (23.97) 40.9 (22.94)
0.501 0.629 0.082
osylated hemoglobin; HOMA  homeostasis model index;
roup as factor.
g/d group.
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Clinical TherapeuticsDISCUSSION
This is a first-in-human study evaluating ITCA 650 in
patients with type 2 diabetes. SC placement of 10-, 20-,
40-, or 80-g/d doses of ITCA 650 resulted in contin-
ous delivery of exenatide over the 28-day treatment
eriod. Significant dose-dependent reductions in FPG,
-hour postprandial glucose, and glucose AUC were
bserved with the 20-, 40-, and 80-g/d doses of ITCA
50. A nonsignificant reduction in these glycemic mea-
ures was also observed with the 10-g/d dose. In ad-
ition, HbA1c decreased significantly in all treatment
groups, and a significant decrease in weight was ob-
served in the 40- and 80-g/d groups.
Other parameters related to glycemic control were
mproved with ITCA 650. Plasma fructosamine, which
s an earlier indicator of glycemic control than
bA1c,
17,18 was significantly decreased in all dose
roups. HOMA-, an indicator of pancreatic -cell
ctivity,19 increased significantly with the 40- and 80-
Table IV. Number (%) of patients experiencing system
Adverse Event 10 g/d (n  12) 20 
Nausea 1 (8.3)
Vomiting 0
Dyspepsia 0
Eructation 0
GERD 0
Abdominal discomfort 0
Early satiety 2 (16.7)
Chills 0
Feeling hot 0
Decreased appetite 4 (33.3)
Hyperlipasemia 0
Hyperamylasemia 0
Hypoglycemia 0
Dizziness 0
Headache 0
Vasovagal syncope 0
Anxiety 0
Hyperhydrosis 0
GERD  gastroesophageal reflux disease.g/d doses of ITCA 650.
642Mean plasma concentrations of exenatide rose in a
dose-dependent manner, reached a plateau at 24 hours
after ITCA 650 placement, and remained relatively
steady over the treatment period. Plasma levels de-
clined rapidly after removal of ITCA 650. At 24 hours
after removal, exenatide levels had fallen below the
level of detection in all patients. This finding is in con-
trast to data reported for exenatide once weekly, which
took 2 weeks to reach therapeutic levels, 6 to 7 weeks
to reach steady-state plasma levels,20 and 6 weeks to
decrease below levels considered to have a therapeutic
effect after treatment cessation.11
ITCA 650 was generally well tolerated by patients.
The most common adverse effects were gastrointesti-
nal (nausea, vomiting, and early satiety). These effects
generally occurred within the first week after place-
ment of ITCA 650, abated with time, and were more
common in the higher dose groups. By week 4, no
patients were experiencing nausea or vomiting, which
eatment-related adverse events (10%).
A 650 Treatment Groups
n  11) 40 g/d (n  10) 80 g/d (n  11)
.3) 6 (60.0) 8 (72.7)
.3) 1 (10.0) 8 (72.7)
0 3 (27.3)
0 3 (27.3)
0 2 (18.2)
1 (10.0) 1 (9.1)
1) 1 (10.0) 1 (9.1)
1 (10.0) 0
1 (10.0) 0
.4) 3 (30.0) 5 (45.5)
1) 1 (10.0) 1 (9.1)
1) 1 (10.0) 0
1 (10.0) 1 (9.1)
2 (20.0) 2 (18.2)
2 (20.0) 1 (9.1)
1 (10.0) 0
1 (10.0) 0
1 (10.0) 0ic tr
ITC
g/d (
3 (27
3 (27
0
0
0
0
1 (9.
0
0
4 (36
1 (9.
1 (9.
0
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0is in contrast to the experience with exenatide BID and
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R.R. Henry et al.exenatide once-weekly injection.12,21 Four of 11 pa-
ients in the 80-g/d dose group discontinued the study
rematurely due to nausea and vomiting. This out-
ome suggests that a lower introductory dose might be
ecessary to mitigate these symptoms. Local effects at
he site of placement/removal were relatively common,
onsistent with the normal reparative process, and
ere mostly mild and self-limiting; none of the local
eactions necessitated removal of ITCA 650.
This study demonstrated that ITCA 650 provides
ontinuous and consistent SC delivery of exenatide
hat was generally well tolerated and may allow for the
dministration of higher doses of exenatide compared
ith exenatide BID. In contrast to the peaks and
roughs in plasma levels noted with exenatide BID in-
ections, constant plasma exenatide concentrations
chieved with ITCA 650 may lead to improved glyce-
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Figure 4. Proportion of patients who experienced
no (A) nausea or (B) vomiting.ic control. Based on the long-term stability of ex-
May 2013natide in the ITCA 650 formulation and the small
aily dosage requirements, a single ITCA 650 can store
nd release exenatide for up to 1 year. In the current
tudy, only 2 patients reported mild episodes of hypo-
lycemia, 1 of which could be more accurately charac-
erized as asymptomatic low blood glucose.
An important barrier to optimizing glycemic control
n patients with type 2 diabetes is poor adherence and
ersistence rates during chronic long-term treatment.
n general, poor adherence to medications is known to
esult in poor disease control and an increase in hospi-
alization and health care costs. Major factors contrib-
ting to poor adherence to diabetes medications are
oncerns regarding the risks of therapy and complex
osing regimens. The need for repeated injections of
LP-1 receptor agonists creates a barrier to long-term
atient adherence and compliance with therapy. Ex-
mination of persistence rates to injectable antidiabe-
es drugs over 12 months from a pharmacy claims da-
abase found a mean persistence of 7.8 months among
atients receiving exenatide injection therapy.22 ITCA
650 may have several advantages compared with ex-
enatide injections and depot formulations of ex-
enatide. The constant delivery of exenatide with ITCA
650 eliminates the peak-to-trough variability in blood
concentrations, which may result in a lower incidence
of adverse reactions compared with the injectable
forms of exenatide. ITCA 650may be easily removed if
necessary to provide an immediate drop in circulating
exenatide plasma levels. The potential to ensure 100%
adherence with ITCA 650 may improve compliance
and adherence and could therefore improve long-term
therapeutic outcomes.22,23
CONCLUSIONS
These preliminary findings of improvement in HbA1c,
asting plasma glucose and other glycemic parameters,
nd weight in this small population of patients with
ype 2 diabetes over a 28-day period of observation are
ncouraging. The results merit longer term, larger scale
tudies to gain further insight into the benefits and risks
f treatment with ITCA 650 in patients with type 2
iabetes.
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Description and summary of implantation procedure for ITCA 650
ITCA 650 utilizes a novel drug delivery technology to provide continuous and controlled subcutaneous delivery
of exenatide for as long as one year of treatment at a precise and predetermined rate. Initiating treatment with ITCA
650 involves the subcutaneous placement of a matchstick-size osmotic mini-pump done during a short office
procedure that can be performed by a physician, physician’s assistant or other licensed practitioner. The figure
provides an illustration of ITCA 650. ITCA 650 consists of a cylindrical titanium alloy reservoir with external
dimensions of 4 mm in diameter by 44 mm in length. The reservoir is capped at one end by a controlled-rate,
semi-permeable membrane and capped at the other end by a diffusion moderator through which drug formulation
is released from the drug reservoir. The drug formulation, piston and osmotic engine are contained inside the
cylinder.
semipermeable
membrane 
osmotic engine piston drug reservoir drug formulation
Schematic of ITCA 650
ITCA 650 releases drug at a predetermined rate based on the principle of osmosis. Water from the extracellular
space enters through the semi-permeable membrane directly into the osmotic engine that expands to drive the
piston at a slow and consistent rate of travel. Movement of the piston forces the drug formulation to be released
through the orifice of the diffusion moderator.
The sterile ITCA 650 is placed in the horizontal plane subcutaneously into one of the four abdominal quadrants
with a placement tool using sterile technique. The intended placement site is marked, cleaned with an antiseptic
agent, draped and anesthetized. Once adequate anesthesia is achieved, a small (5mm deep) incision is made. The
ip of the cannula of the placement tool that has been loaded with the ITCA 650 is inserted into the incision. The
ool is immediately leveled and advanced parallel to the surface of the skin to an indicator band on the placement
ool. The cannula of the placement tool is then retracted into its handle, leaving the ITCA 650 in position directly
nder the skin. The incision is then closed with Steri-StripsTM and covered with a bandage.
Removal requires similar skin preparation and adherence to sterile technique as placement. The ITCA 650 is
immobilized and a small (5 mm) incision is made directly over one end of the device. The ITCA 650 is then gently
pushed towards the incision and removed with a hemostat.
A new ITCA 650 can be placed in the same incision from which the old device has been removed. The incision
is then closed with Steri-StripsTM and covered with a bandage. Patients are instructed to keep the area clean and dry
for 24 hours, to allow the Steri-StripsTM to fall off, and to avoid heavy lifting and strenuous physical activity for 48
hours.645.e1 Volume 35 Number 5
